DAB2IP Expression in Bladder Transitional Cell Carcinoma and Its Correlation with Clinical Outcome

ZHU Jian-ning, WU Kai-jie, GUAN Zhen-feng. et al

Abstract

To investigate the expression of DAB2IP in bladder transitional cell carcinoma (BTCC) and its correlation with clinical characteristics and prognosis of BTCC patients. Methods Immunohistochemical staining was applied to detect DAB2IP protein level in 79 cases of TCCB tissues and 11 cases of normal bladder tissues, and the relationships of the staining results with pathological grade, stage, lymph node metastasis, gender, age and the 3-year survival rate of the patients were analyzed. Results The expression of DAB2IP in BTCC tissues was significantly lower than that in normal bladder epithelium, and the expression score and rate of DAB2IP in the high-grade, invasive and metastatic BTCC were significantly lower than those in low-grade, superficial and non-metastatic BTCC (P<0.05).The 3-year survival rate of the patients with high DAB2IP expression was significantly higher than that of the patients with low DAB2IP expression. Conclusion DAB2IP may be one of the important inhibitory factors during the occurrence and progression of BTCC.

 

Keywords: Bladder cancer, DAB2IP Immunohistochemistry 3-year survival rate 

 

Full Text:

PDF


References


Mhawech-Fauceglia P. Cheney RT. Fischer G. et al. FGFR3 and p53 protein expressions in patients with pTa and pTl urothelial bladder cancer. Fur J Surg Oncol. 2006; 32 (2); 231- 237.

Margulis V. Lotan Y. Karakiewicz PI. et al. Multi- institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst ,2009 ; 101(2) : 114-119.

Shariat SF. Ashfaq R. Karakiewicz PI. et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer,2007; 109(6); 1106-1113.

Wang Z, Tseng CP, Hsieh JT, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem.2002;277( 15): 12622-12631.

Chen H. Pong RC. Hsieh JT. et al. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia;cloning and characterization. Genomics.2002;79(4): 573-581.

Dote H. Toyooka S. Shimizu N. et al. Aberrant promoter methylation in human DAB2 interactive protein ( hDAB2IP) gene in gastrointestinal tumour. Br J Cancer, 2005; 92 ( 6 ): 1117-1125.

Yano M, Toyooka S, Shimizu N, et al. Aberrant promoter methylation of human DAB2 interactive protein ( hDAB2IP) gene in lung cancers. Int J Cancer,2005; 113( 1):59-66.

QiuGH. Xie H, Hooi SC, et al. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol. 2007 ;46(4): 655-663.

Tseng CP, Ely BD, Hsieh JT, et al. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology,1998; 139(8):3542-3553.

Min J. Zaslavsky A, Beroukhim R. et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med.2010; 16(3):286-294.

Zhang H,Zhang R.Luo Y.et al. AIP/DAB2IP,a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1- JNK activation. J Biol Chem,2004 ;279(43);44955-44965.

Xie D.Gore С, Zhou J .et al. DAB2IP coordinates both PI3K- Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA,2009; 106(47): 19878-19883.

Xie D. Gore C, Liu J, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA,2010; 107(6) :2485-2490.

Chen H.Toyooka S.Gazdar AF,et al. Epigenetic regulation of a novel tumor suppressor gene(h DAB2IP) in prostate cancer cell lines. J Biol Chem,2003;278(5) :3121-3130.


Refbacks

  • There are currently no refbacks.